Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Linehan Website

W. Marston Linehan, M.D.

Selected Publications

1)  Koch C, Walther M, Linehan W.
Chrousos G, eds.
Von Hippel-Lindau Syndrome. In: Adrenal Physiology and Diseases.
2019. In Press. [Book Chapter]
2)  Srinivasan R, Linehan W.
Wein A, eds.
Treatment of Advanced Renal Cell Carcinoma. In: Campbell-Walsh Urology. Volume 63.
Philadelphia: Elsevier; 2019. In Press. [Book Chapter]
3)  Linehan W, Schmidt L.
DeVita V, Lawrence T, Rosenberg S, eds.
Molecular Biology of Kidney Cancer. In: Cancer: Principles and Practice of Oncology.
New Haven: Lippincott Williams & Wilkins; 2019. In Press. [Book Chapter]
4)  Srinivasan R, Linehan W.
Lifton R, eds.
The Genetic Basis of Cancer of the Kidney. In: Genetic Diseases of the Kidney.
San Diego: Elsevier; 2019. In Press. [Book Chapter]
5)  Paulter S, Walther M, Merino M, Schmidt L, Zbar B, Choyke P, Glenn G, Linehan W.
A Novel Germline Met Mutation Leading to Papillary Renal Cell Carcinoma.
Journal of Urology. 2019.
In Press. [Journal]
6)  Singer E, Williams H, Neckers L, Fowler S, Gautam R, Turkbey B, Choyke P, Pinto P, Bratslavsky G, Linehan W, Srinivasan R.
A Phase II Study of 17-Allylamino-17-Demethoxygeldanamycin (17AAG) in Patients With Von Hippel-Lindau (VHL) Disease and Renal Tumors.
J Cancer. 2019.
In Press. [Journal]
7)  Linehan W.
Birt-Hogg-Dube Syndrome.
Familial Cancer. 2019.
In Press. [Journal]
8)  Nix J, Shuch B, Linehan W.
Clinical Features and Management of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC).
Unknown. 2019.
In Press. [Journal]
9)  Nix J, Linehan W.
Clinical Features and Management of Hereditary Leomyomatosis and Renal Cell Cancer (HLRCC): An Aggressive Form of Type II Papillary Kidney Cancer Characterized by Germline Mutation of the Krebs Cycle Enzyme Gene Fumarate Hydratase.
Unknown. 2019.
In Press. [Journal]
10)  Kauffman E, Shuch B, Rais-Bahrami S, Yang Y, Merino M, Srinivasan R, Linehan W.
Clinical Features of MiT Family Gene Fusions in Renal Cell Carcinoma and Recommendations for Clinical Management.
Journal of Urology. 2019.
In Press. [Journal]
11)  Linehan W.
Eur Urol. 2019.
In Press. [Journal]
12)  Pacak K, Eisenhofer G, Walther M, Carrasquillo J, Chen C, Whatley M, Linehan W, Goldstein D.
Efficacy of 6-[18F] Fluorodopamine Positron Emission Tomography for Diagnostic Localization of Pheochromocytoma in Difficult Cases.
New England Journal of Medicine. 2019.
In Press. [Journal]
13)  Summers R, Agcaoili C, McAuliffe M, Dalal S, Yim P, Choyke P, Linehan W.
Helical CT of Von Hippel-Lindau: Semi-Automated Segmentation of Renal Lesions.
Unknown. 2019.
In Press. [Journal]
14)  Kauffman E, Ricketts C, Rais-Bahrami S, Yang Y, Merino M, Bottaro D, Srinivasan R, Linehan W.
Molecular Genetics and Oncogenic Mechanisms of TFE3 and TFEB Gene Fusions in Renal Cell Carcinoma.
Nature Reviews Urol. 2019.
In Press. [Journal]
15)  Paulters S, Meadows M, Glenn G, Merino M, Choyke P, Wall W, Turnball D, Linehan W, Chin J.
Multifocal Renal Cell Carcinoma Following Liver Transplantation for Sclerosing Cholangitis.
Journal of Urology. 2019.
In Press. [Journal]
16)  Losner R, Butman J, Huntoon K, Asthagiri A, Wu T, Bakhtian K, Chew E, Zhuang Z, Linehan W, Oldfield E.
Natural History of Central Nervous System Haemangioblastomas in Von Hippel-Lindau Disease.
Lancet. 2019.
In Press. [Journal]
17)  Weintraub M, Siddiqui M, Vourganti S, Shuch B, Ricketts C, Nix J, Rosen P, Linehan W, Agarwal P.
Partial Robotic Cystectomy in the Treatment of a Paraganglioma of the Urinary Bladder.
J Endourol. 2019.
In Press. [Journal]
18)  Brooks S, Linehan W, Srinivasan R.
Patient With Perifollicular Dark Blue-Gray Macular Hyperpigmentation Secondary to Vandetanib Who Was Successfully Treated With 775 Nm Q-Switched Alexandrite Laser.
Unknown. 2019.
In Press. [Journal]
19)  Ishibe N, Corbin N, Paulter S, Linehan W, Glenn G.
Phenocopies With Sporadic Clear Cell Renal Carcinoma Within Von Hippel-Lindau Syndrome Kindreds.
Nat Clin Pract Urol. 2019.
In Press. [Journal]
20)  Chernoff A, Ornstein D, Leach F, Choyke P, Walther M, Linehan W, Collins M.
Testicular Abnormalities in the McCune-Albright Syndrome: Report of 4 Cases and Review of the Literature.
Unknown. 2019.
In Press. [Journal]
21)  Chian-Garcia C, Torres-Cabala C, Wrathall L, Linehan W, Merino M.
The Spectrum of Renal Cell Carcinoma in Children and Young Adults.
Unknown. 2019.
In Press. [Journal]
22)  Shuch B, Linehan WM, Srinivasan R.
Aerobic glycolysis: a novel target in kidney cancer.
Expert Rev Anticancer Ther. 13: 711-9, 2013.
23)  Ballester L, Aung P, Lai J, DiGiovanna J, Abdullaev Z, Pack S, Linehan W, Stern J, Pinto P, Lee C.
An Unusual Presentation of Glomeruloid Mehangioma in a Patient With VHL Syndrome: A Case Report and Review of Literature.
Open J Clin Diagnostics. 3: June 1-4, 2013.
24)  Stamatakis L, Metwalli AR, Middelton LA, Marston Linehan W.
Diagnosis and management of BHD-associated kidney cancer.
Fam. Cancer. 2013.
25)  Farley MN, Schmidt LS, Mester JL, Pena-Llopis S, Pavia-Jimenez A, Christie A, Vocke CD, Ricketts CJ, Peterson J, Middelton L, Kinch L, Grishin N, Merino MJ, Metwalli AR, Xing C, Xie XJ, Dahia PL, Eng C, Linehan WM, Brugarolas J.
Germline BAP1 mutation predisposes to familial clear-cell renal cell carcinoma.
Mol. Cancer Res. 2013.
26)  Shuch B, Ricketts CJ, Vocke CD, Komiya T, Middelton LA, Kauffman EC, Merino MJ, Metwalli AR, Dennis P, Linehan WM.
Germline PTEN Mutation Cowden Syndrome: An Under-Appreciated Form of Hereditary Kidney Cancer.
J. Urol. 2013.
27)  Partanen A, Yerram NK, Trivedi H, Dreher MR, Oila J, Hoang AN, Volkin D, Nix J, Turkbey B, Bernardo M, Haines DC, Benjamin CJ, Linehan WM, Choyke P, Wood BJ, Ehnholm GJ, Venkatesan AM, Pinto PA.
Magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy of the prostate: a preclinical study with radiological and pathological correlation using customised MRI-based moulds.
BJU Int. 112: 508-16, 2013.
28)  Yang Y, Lane AN, Ricketts CJ, Sourbier C, Wei MH, Shuch B, Pike L, Wu M, Rouault TA, Boros LG, Fan TW, Linehan WM.
Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma.
PLoS ONE. 8: e72179, 2013.
29)  Linehan WM, Rouault TA.
Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer.
Clin. Cancer Res. 19: 3345-52, 2013.
30)  Neckers L, Ricketts CJ, Marston Linehan W.
New Insights into von Hippel-Lindau Function Highlighted by Investigation of the Trichloroethylene-Induced p.P81S Hotspot Mutation.
J. Natl. Cancer Inst. 2013.
31)  Chow WH, Linehan WM, Devesa SS.
Reply to Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics.
Cancer. 119: 3101, 2013.
32)  Nickerson ML, Im KM, Misner KJ, Tan W, Lou H, Gold B, Wells DW, Bravo HC, Fredrikson KM, Harkins TT, Milos P, Zbar B, Linehan WM, Yeager M, Andresson T, Dean M, Bova GS.
Somatic alterations contributing to metastasis of a castration-resistant prostate cancer.
Hum. Mutat. 34: 1231-41, 2013.
33)  Linehan W, Vocke C, Peterson J, Merino M, Schmidt L, Ricketts C.
The Cancer Genome Atlas Research Network: Comprehensive Molecular Characterization of Clear Cell Renal Cell Carcinoma.
Nature. 499: 43-49, 2013.
34)  Zhong M, Weisman P, Zhu B, Brassesco M, Yang Y, Linehan WM, Merino MJ, Zhang D, Rohan S, Cai D, Yang X.
Xp11.2 translocation renal cell carcinoma with PSF-TFE3 rearrangement.
Diagn. Mol. Pathol. 22: 107-11, 2013.
35)  Schmidt L, Srinivasan R, Linehan W.
The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies. In: Renal Cell Carcinoma: Biology, Prognostic Factors and Therapeutic Targets.
2013. In Press. [Book Chapter]
36)  Shuch B, Ricketts CJ, Vocke CD, Valera VA, Chen CC, Gautam R, Gupta GN, Gomez Macias GS, Merino MJ, Bratslavsky G, Linehan WM.
Adrenal nodular hyperplasia in hereditary leiomyomatosis and renal cell cancer.
J. Urol. 189: 430-5, 2013.
37)  Purdue MP, Moore LE, Merino MJ, Boffetta P, Colt JS, Schwartz KL, Bencko V, Davis FG, Graubard BI, Janout V, Ruterbusch JJ, Beebe-Dimmer J, Cote ML, Shuch B, Mates D, Hofmann JN, Foretova L, Rothman N, Szeszenia-Dabrowska N, Matveev V, Wacholder S, Zaridze D, Linehan WM, Brennan P, Chow WH.
An investigation of risk factors for renal cell carcinoma by histologic subtype in two case-control studies.
Int. J. Cancer. 132: 2640-7, 2013.
38)  Sourbier C, Scroggins BT, Ratnayake R, Prince TL, Lee S, Lee MJ, Nagy PL, Lee YH, Trepel JB, Beutler JA, Linehan WM, Neckers L.
Englerin A stimulates PKC? to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality.
Cancer Cell. 23: 228-37, 2013.
39)  Boris RS, Gupta GN, Benson JS, Linehan WM, Pinto PA, Bratslavsky G.
Feasibility and outcomes of laparoscopic renal intervention after prior open ipsilateral retroperitoneal surgery.
J. Endourol. 27: 196-201, 2013.
40)  Shankavaram U, Fliedner SM, Elkahloun AG, Barb JJ, Munson PJ, Huynh TT, Matro JC, Turkova H, Linehan WM, Timmers HJ, Tischler AS, Powers JF, de Krijger R, Baysal BE, Takacova M, Pastorekova S, Gius D, Lehnert H, Camphausen K, Pacak K.
Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas.
Neoplasia. 15: 435-47, 2013.
41)  Liu NW, Sanford T, Srinivasan R, Liu JL, Khurana K, Aprelikova O, Valero V, Bechert C, Worrell R, Pinto PA, Yang Y, Merino M, Linehan WM, Bratslavsky G.
Impact of ischemia and procurement conditions on gene expression in renal cell carcinoma.
Clin. Cancer Res. 19: 42-9, 2013.
42)  Sudarshan S, Karam JA, Brugarolas J, Thompson RH, Uzzo R, Rini B, Margulis V, Patard JJ, Escudier B, Linehan WM.
Metabolism of kidney cancer: from the lab to clinical practice.
Eur. Urol. 63: 244-51, 2013.
43)  Sanz-Ortega J, Vocke C, Stratton P, Linehan WM, Merino MJ.
Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
Am. J. Surg. Pathol. 37: 74-80, 2013.
44)  Shuch B, Hofmann JN, Merino MJ, Nix JW, Vourganti S, Linehan WM, Schwartz K, Ruterbusch JJ, Colt JS, Purdue MP, Chow W.
Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program.
Urol Oncol. [Epub ahead of print], 2013.
45)  Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R.
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
J. Clin. Oncol. 31: 181-6, 2013.
46)  Turkbey B, Mani H, Aras O, Ho J, Hoang A, Rastinehad AR, Agarwal H, Shah V, Bernardo M, Pang Y, Daar D, McKinney YL, Linehan WM, Kaushal A, Merino MJ, Wood BJ, Pinto PA, Choyke PL.
Prostate Cancer: Can Multiparametric MR Imaging Help Identify Patients Who Are Candidates for Active Surveillance?.
Radiology. [Epub ahead of print], 2013.
47)  Chow WH, Shuch B, Linehan WM, Devesa SS.
Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics.
Cancer. 119: 388-94, 2013.
48)  Liu Q, Galli S, Srinivasan R, Linehan WM, Tsokos M, Merino MJ.
Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation.
Am. J. Surg. Pathol. 37: 368-74, 2013.
49)  Kim HJ, Hagan M, Butman JA, Baggenstos M, Brewer C, Zalewski C, Linehan WM, Lonser RR.
Surgical resection of endolymphatic sac tumors in von Hippel-Lindau disease: findings, results, and indications.
Laryngoscope. 123: 477-83, 2013.
50)  Filson CP, Schwartz K, Colt JS, Ruterbusch J, Linehan WM, Chow W, Miller DC.
Use of nephron-sparing surgery among renal cell carcinoma patients with diabetes and hypertension.
Urol. Oncol. [Epub ahead of print], 2013.
51)  Srinivasan R, Linehan WM.
Treatment of Advanced Renal Cell Carcinoma. In: Campbell-Walsh Urology. Volume 50.
Philadelphia: Elsevier; 2012. p. 1475-1491 [Book Chapter]
52)  Mena E, Turkbey B, Mani H, Adler S, Valera VA, Bernardo M, Shah V, Pohida T, McKinney Y, Kwarteng G, Daar D, Lindenberg ML, Eclarinal P, Wade R, Linehan WM, Merino MJ, Pinto PA, Choyke PL, Kurdziel KA.
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation.
J. Nucl. Med. 53: 538-45, 2012.
53)  Yang Y, Valera V, Sourbier C, Vocke CD, Wei M, Pike L, Huang Y, Merino MA, Bratslavsky G, Wu M, Ricketts CJ, Linehan WM.
A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer.
Cancer Genet. 205: 377-90, 2012.
54)  Weisbrod AB, Liewehr DJ, Steinberg SM, Patterson EE, Libutti SK, Linehan WM, Nilubol N, Kebebew E.
Association of type O blood with pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome.
Ann. Surg. Oncol. 19: 2054-9, 2012.
55)  Boyce AM, Chong WH, Shawker TH, Pinto PA, Linehan WM, Bhattacharryya N, Merino MJ, Singer FR, Collins MT.
Characterization and Management of Testicular Pathology in McCune-Albright Syndrome.
J Clin Endocrinol Metabol. 97: E1782-90, 2012.
56)  Weisbrod AB, Kitano M, Gesuwan K, Millo C, Herscovitch P, Nilubol N, Linehan WM, Kebebew E.
Clinical utility of functional imaging with 18F-FDOPA in Von Hippel-Lindau syndrome.
J. Clin. Endocrinol. Metab. 97: E613-7, 2012.
57)  Turkbey B, Mani H, Aras O, Rastinehad AR, Shah V, Bernardo M, Pohida T, Daar D, Benjamin C, McKinney YL, Linehan WM, Wood BJ, Merino MJ, Choyke PL, Pinto PA.
Correlation of magnetic resonance imaging tumor volume with histopathology.
J. Urol. 188: 1157-63, 2012.
58)  Agochukwu NQ, Metwalli AR, Kutikov A, Pinto PA, Linehan WM, Bratslavsky G.
Economic burden of repeat renal surgery on solitary kidney--do the ends justify the means? A cost analysis.
J. Urol. 188: 1695-700, 2012.
59)  Linehan WM.
Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics.
Genome Res. 22: 2089-100, 2012.
60)  Eisenhofer G, Vocke CD, Elkahloun A, Huynh TT, Prodanov T, Lenders JW, Timmers HJ, Benhammou JN, Linehan WM, Pacak K.
Genetic Screening for von Hippel-Lindau Gene Mutations in Non-syndromic Pheochromocytoma: Low Prevalence and False-positives or Misdiagnosis Indicate a Need for Caution.
Horm. Metab. Res. 44: 343-8, 2012.
61)  Moore LE, Jaeger E, Nickerson ML, Brennan P, De Vries S, Roy R, Toro J, Li H, Karami S, Lenz P, Zaridze D, Janout V, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Linehan WM, Merino M, Simko J, Pfeiffer R, Boffetta P, Hewitt S, Rothman N, Chow WH, Waldman FM.
Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation.
Oncogenesis. 1: e14, 2012.
62)  Hoang AN, Volkin D, Yerram NK, Vourganti S, Nix J, Linehan WM, Wood B, Pinto PA.
Image guidance in the focal treatment of prostate cancer.
Curr Opin Urol. 22: 328-35, 2012.
63)  Shuch B, Bratslavsky G, Shih J, Vourganti S, Finley D, Castor B, Treat E, Linehan WM, Pantuck AJ, Said JW, Belldegrun AS.
Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma.
BJU Int. 109: 1600-6, 2012.
64)  McKee TC, Rabe D, Bokesch HR, Grkovic T, Whitson EL, Diyabalanage T, Van Wyk AW, Marcum SR, Gardella RS, Gustafson KR, Linehan WM, McMahon JB, Bottaro DP.
Inhibition of hypoxia inducible factor-2 transcription: isolation of active modulators from marine sponges.
J. Nat. Prod. 75: 1632-6, 2012.
65)  Linehan WM, Rathmell WK.
Kidney cancer.
Urol. Oncol. 30: 948-51, 2012.
66)  Shuch B, Linehan WM.
Kidney cancer: Is incomplete renal ablation linked to tumour progression?.
Nat Rev Urol. 9: 547-8, 2012.
67)  Woldemichael GM, Turbyville TJ, Vasselli JR, Linehan WM, McMahon JB.
Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A.
Neoplasia. 14: 771-7, 2012.
68)  Yerram NK, Volkin D, Turkbey B, Nix J, Hoang AN, Vourganti S, Gupta GN, Linehan WM, Choyke PL, Wood BJ, Pinto PA.
Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer.
BJU Int. 110: E783-8, 2012.
69)  Vourganti S, Rastinehad A, Yerram NK, Nix J, Volkin D, Hoang A, Turkbey B, Gupta GN, Kruecker J, Linehan WM, Choyke PL, Wood BJ, Pinto PA.
Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies.
J. Urol. 188: 2152-7, 2012.
70)  Singer EA, Vourganti S, Lin KY, Gupta GN, Pinto PA, Rastinehad AR, Linehan WM, Bratslavsky G.
Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of followup.
J. Urol. 188: 2084-8, 2012.
71)  Volkin D, Yerram N, Ahmed F, Lankford D, Baccala A, Gupta GN, Hoang A, Nix J, Metwalli AR, Lang DM, Bratslavsky G, Linehan WM, Pinto PA.
Partial adrenalectomy minimizes the need for long-term hormone replacement in pediatric patients with pheochromocytoma and von Hippel-Lindau syndrome.
J. Pediatr. Surg. 47: 2077-82, 2012.
72)  Eisenhofer G, Lenders W, Siegert G, Bornstein S, Friberg P, Milosevic D, Mannelli M, Linehan W, Adams K, Timmers H, Pacak K.
Plasma Methoxytyramine: A Novel Biomarker of Metastatic Pheochromocytoma in Relation to Established Risk Factors of Tumor Size, Location and SDHB Mutation Status.
Eur J Cancer. 48: 1739-1749, 2012.
73)  Aung PP, Killian K, Poropatich CO, Linehan WM, Merino MJ.
Primary neuroendocrine tumors of the kidney: morphological and molecular alterations of an uncommon malignancy.
Hum. Pathol. [Epub ahead of print], 2012.
74)  Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS, DeBerardinis RJ.
Reductive carboxylation supports growth in tumour cells with defective mitochondria.
Nature. 481: 385-8, 2012.
75)  Hasumi H, Baba M, Hasumi Y, Huang Y, Oh H, Hughes RM, Klein ME, Takikita S, Nagashima K, Schmidt LS, Linehan WM.
Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN.
J. Natl. Cancer Inst. 104: 1750-64, 2012.
76)  Shuch B, Bratslavsky G, Linehan WM, Srinivasan R.
Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies.
Oncologist. 17: 46-54, 2012.
77)  Ricketts CJ, Shuch B, Vocke CD, Metwalli AR, Bratslavsky G, Middelton L, Yang Y, Wei MH, Pautler SE, Peterson J, Stolle CA, Zbar B, Merino MJ, Schmidt LS, Pinto PA, Srinivasan R, Pacak K, Linehan WM.
Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer.
J. Urol. 188: 2063-71, 2012.
78)  Teicher BA, Linehan WM, Helman LJ.
Targeting cancer metabolism.
Clin. Cancer Res. 18: 5537-45, 2012.
79)  Sourbier C, Srivastava G, Ghosh MC, Ghosh S, Yang Y, Gupta G, Degraff W, Krishna MC, Mitchell JB, Rouault TA, Linehan WM.
Targeting HIF2a translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Oncotarget. 3: 1472-82, 2012.
80)  Shuch B, Vourganti S, Friend JC, Zehngebot LM, Linehan WM, Srinivasan R.
Targeting the mTOR pathway in Chromophobe Kidney Cancer.
J Cancer. 3: 152-7, 2012.
81)  Baba M, Keller JR, Sun H, Resch W, Kuchen S, Suh HC, Hasumi H, Hasumi Y, Kieffer-Kwon K, Gonzalez CG, Hughes RM, Klein ME, Oh HF, Bible P, Southon E, Tessarollo L, Schmidt LS, Linehan WM, Casellas R.
The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dube syndrome is required for mouse B cell development.
Blood. 120: 1254-61, 2012.
82)  Linehan WM.
The genetic basis of kidney cancer: implications for management and use of targeted therapeutic approaches.
Eur. Urol. 61: 896-8, 2012.
83)  Linehan WM, Ricketts CJ.
The metabolic basis of kidney cancer.
Semin Cancer Biol. 23: 46-55, 2012.
84)  Zhong M, De Angelo P, Osborne L, Paniz-Mondolfi AE, Geller M, Yang Y, Linehan WM, Merino MJ, Cordon-Cardo C, Cai D.
Translocation renal cell carcinomas in adults: a single-institution experience.
Am. J. Surg. Pathol. 36: 654-62, 2012.
85)  Trivedi H, Turkbey B, Rastinehad AR, Benjamin CJ, Bernardo M, Pohida T, Shah V, Merino MJ, Wood BJ, Linehan WM, Venkatesan AM, Choyke PL, Pinto PA.
Use of patient-specific MRI-based prostate mold for validation of multiparametric MRI in localization of prostate cancer.
Urology. 79: 233-9, 2012.
86)  Nix JW, Turkbey B, Hoang A, Volkin D, Yerram N, Chua C, Linehan WM, Wood B, Choyke P, Pinto PA.
Very distal apical prostate tumours: identification on multiparametric MRI at 3 Tesla.
BJU Int. 110: E694-700, 2012.
87)  Turcotte S, Turkbey B, Barak S, Libutti SK, Alexander HR, Linehan WM, Hughes MS, Nilubol N, Gesuwan K, Millo C, Quezado M, Choyke PL, Kebebew E, Phan GQ.
von Hippel-Lindau disease-associated solid microcystic serous adenomas masquerading as pancreatic neuroendocrine neoplasms.
Surgery. 152: 1106-17, 2012.
88)  Fonte J, Breza J, Linehan W, Bratslavsky G, Pacak K.
Diagnosis and Management of Pheochromocytoma. In: Comprehensive Textbook of Genitourinary Oncology. Volume 51.
Philadelphia: Lippincott Williams & Wilkins; 2011. p. 859-869 [Book Chapter]
89)  Bratslavsky G, Pinto P, Linehan WM.
Management of Inherited Forms of Renal Cancer. In: Comprehensive Textbook of Genitourinary Oncology. Volume 4.
Philadelphia: Lippincott Williams & Wilkins; 2011. p. 762-768 [Book Chapter]
90)  Bokesch HR, Gardella RS, Rabe DC, Bottaro DP, Linehan WM, McMahon JB, McKee TC.
A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum.
Chem. Pharm. Bull. 59: 1178-9, 2011.
91)  Eisenhofer G, Timmers HJ, Lenders JW, Bornstein SR, Tiebel O, Mannelli M, King KS, Vocke CD, Linehan WM, Bratslavsky G, Pacak K.
Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location.
J. Clin. Endocrinol. Metab. 96: 375-84, 2011.
92)  Bratslavsky G.
Argument in favor of performing partial nephrectomy for tumors greater than 7 cm: the metastatic prescription has already been written.
Urol. Oncol. 29: 829-32, 2011.
93)  Linguraru MG, Wang S, Shah F, Gautam R, Peterson J, Linehan WM, Summers RM.
Automated noninvasive classification of renal cancer on multiphase CT.
Med Phys. 38: 5738-46, 2011.
94)  Woldemichael GM, Turbyville TJ, Linehan WM, McMahon JB.
Carminomycin I is an apoptosis inducer that targets the Golgi complex in clear cell renal carcinoma cells.
Cancer Res. 71: 134-42, 2011.
95)  Eisenhofer G, Pacak K, Huynh TT, Qin N, Bratslavsky G, Linehan WM, Mannelli M, Friberg P, Grebe SK, Timmers HJ, Bornstein SR, Lenders JW.
Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma.
Endocr. Relat. Cancer. 18: 97-111, 2011.
96)  Kitano M, Millo C, Rahbari R, Herscovitch P, Gesuwan K, Webb RC, Venkatesan AM, Phan GQ, Hughes MS, Libutti SK, Nilubol N, Linehan WM, Kebebew E.
Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease.
Surgery. 150: 1122-8, 2011.
97)  Rastinehad AR, Baccala AA, Chung PH, Proano JM, Kruecker J, Xu S, Locklin JK, Turkbey B, Shih J, Bratslavsky G, Linehan WM, Glossop ND, Yan P, Kadoury S, Choyke PL, Wood BJ, Pinto PA.
D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging.
J. Urol. 185: 815-20, 2011.
98)  Bratslavsky G, Sanford T, Srinivasan R, Aprelikova O, Liu J, Quezado M, Merino M, Linehan WM.
Differential genetic expression in large versus small clear cell renal cell carcinoma: results from microarray analysis.
J Cancer. 2: 271-9, 2011.
99)  Shuch B, Pacak K, Linehan WM, Bratslavsky G.
Editorial comment.
J. Urol. 185: 1589-90; author reply 1590, 2011.
100)  Singer EA, Srinivasan R, Bratslavsky G.
Editorial comment.
J. Urol. 185: 66, 2011.
101)  Barrisford GW, Singer EA, Rosner IL, Linehan WM, Bratslavsky G.
Familial renal cancer: molecular genetics and surgical management.
Int J Surg Oncol. 2011: 658767, 2011.
102)  Fadahunsi AT, Sanford T, Linehan WM, Pinto PA, Bratslavsky G.
Feasibility and outcomes of partial nephrectomy for resection of at least 20 tumors in a single renal unit.
J. Urol. 185: 49-53, 2011.
103)  Grkovic T, Whitson EL, Rabe DC, Gardella RS, Bottaro DP, Linehan WM, McMahon JB, Gustafson KR, McKee TC.
Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2α induced gene expression.
Bioorg. Med. Chem. Lett. 21: 2113-5, 2011.
104)  Benhammou JN, Vocke CD, Santani A, Schmidt LS, Baba M, Seyama K, Wu X, Korolevich S, Nathanson KL, Stolle CA, Linehan WM.
Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dubé syndrome.
Genes Chromosomes Cancer. 50: 466-77, 2011.
105)  Singer EA, Bratslavsky G, Middelton L, Srinivasan R, Linehan WM.
Impact of genetics on the diagnosis and treatment of renal cancer.
Curr Urol Rep. 12: 47-55, 2011.
106)  Cherkasova E, Malinzak E, Rao S, Takahashi Y, Senchenko VN, Kudryavtseva AV, Nickerson ML, Merino M, Hong JA, Schrump DS, Srinivasan R, Linehan WM, Tian X, Lerman MI, Childs RW.
Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer.
Oncogene. 2011.
107)  Pinto PA, Chung PH, Rastinehad AR, Baccala AA, Kruecker J, Benjamin CJ, Xu S, Yan P, Kadoury S, Chua C, Locklin JK, Turkbey B, Shih JH, Gates SP, Buckner C, Bratslavsky G, Linehan WM, Glossop ND, Choyke PL, Wood BJ.
Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging.
J. Urol. 186: 1281-5, 2011.
108)  Eisenhofer G, Lenders JW, Timmers H, Mannelli M, Grebe SK, Hofbauer LC, Bornstein SR, Tiebel O, Adams K, Bratslavsky G, Linehan WM, Pacak K.
Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma.
Clin. Chem. 57: 411-20, 2011.
109)  Sanford T, Chung PH, Reinish A, Valera V, Srinivasan R, Linehan WM, Bratslavsky G.
Molecular sub-classification of renal epithelial tumors using meta-analysis of gene expression microarrays.
PLoS ONE. 6: e21260, 2011.
110)  Turkbey B, Mani H, Shah V, Rastinehad AR, Bernardo M, Pohida T, Pang Y, Daar D, Benjamin C, McKinney YL, Trivedi H, Chua C, Bratslavsky G, Shih JH, Linehan WM, Merino MJ, Choyke PL, Pinto PA.
Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds.
J. Urol. 186: 1818-24, 2011.
111)  Kearney MF, Lee K, Bagni RK, Wiegand A, Spindler J, Maldarelli F, Pinto PA, Linehan WM, Vocke CD, Delviks-Frankenberry KA, Devere White RW, Del Prete GQ, Mellors JW, Lifson JD, Kewalramani VN, Pathak VK, Coffin JM, Le Grice SF.
Nucleic Acid, Antibody, and Virus Culture Methods to Detect Xenotropic MLV-Related Virus in Human Blood Samples.
Adv Virol. 2011: 272193, 2011.
112)  Sanford TH, Storey BB, Linehan WM, Rogers CA, Pinto PA, Bratslavsky G.
Outcomes and timing for intervention of partial adrenalectomy in patients with a solitary adrenal remnant and history of bilateral phaeochromocytomas.
BJU Int. 107: 571-5, 2011.
113)  Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, Mannelli M, Linehan WM, Adams K, Timmers HJ, Pacak K.
Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
Eur. J. Cancer. 2011.
114)  Valera VA, Walter BA, Linehan WM, Merino MJ.
Regulatory Effects of microRNA-92 (miR-92) on VHL Gene Expression and the Hypoxic Activation of miR-210 in Clear Cell Renal Cell Carcinoma.
J Cancer. 2: 515-26, 2011.
115)  Chung PH, Srinivasan R, Linehan WM, Pinto PA, Bratslavsky G.
Renal cell carcinoma with metastases to the gallbladder: Four cases from the National Cancer Institute (NCI) and review of the literature.
Urologic oncology. 2011.
116)  Shuch B, Linehan WM, Bratslavsky G.
Repeat partial nephrectomy: surgical, functional and oncological outcomes.
Curr Opin Urol. 21: 368-75, 2011.
117)  Asher KP, Gupta GN, Boris RS, Pinto PA, Linehan WM, Bratslavsky G.
Robot-assisted laparoscopic partial adrenalectomy for pheochromocytoma: the National Cancer Institute technique.
Eur. Urol. 60: 118-24, 2011.
118)  Boris RS, Gupta G, Linehan WM, Pinto PA, Bratslavsky G.
Robot-assisted laparoscopic partial adrenalectomy: initial experience.
Urology. 77: 775-80, 2011.
119)  Gupta GN, Boris R, Chung P, Marston Linehan W, Pinto PA, Bratslavsky G.
Robot-assisted laparoscopic partial nephrectomy for tumors greater than 4 cm and high nephrometry score: Feasibility, renal functional, and oncological outcomes with minimum 1 year follow-up.
Urol. Oncol. 2011.
120)  Brooks S, Linehan WM, Srinivasan R, Kong HH.
Successful laser treatment of vandetanib-associated cutaneous pigmentation.
Arch Dermatol. 147: 364-5, 2011.
121)  Bratslavsky G, Linehan WM.
Surgery: Routine adrenalectomy in renal cancer--an antiquated practice.
Nat Rev Urol. 8: 534-6, 2011.
122)  Filson CP, Miller DC, Colt JS, Ruterbusch J, Linehan WM, Chow WH, Schwartz K.
Surgical approach and the use of lymphadenectomy and adrenalectomy among patients undergoing radical nephrectomy for renal cell carcinoma.
Urologic oncology. 2011.
123)  Vourganti S, Shuch B, Bratslavsky G.
Surgical management of large renal tumors.
Expert Rev Anticancer Ther. 11: 1889-900, 2011.
124)  Tong WH, Sourbier C, Kovtunovych G, Jeong SY, Vira M, Ghosh M, Romero VV, Sougrat R, Vaulont S, Viollet B, Kim YS, Lee S, Trepel J, Srinivasan R, Bratslavsky G, Yang Y, Linehan WM, Rouault TA.
The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.
Cancer Cell. 20: 315-27, 2011.
125)  Boris RS, Benhammou J, Merino M, Pinto PA, Linehan WM, Bratslavsky G.
The impact of germline BHD mutation on histological concordance and clinical treatment of patients with bilateral renal masses and known unilateral oncocytoma.
J. Urol. 185: 2050-5, 2011.
126)  Moore LE, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J, Han SS, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Schmidt LS, Lenz P, Karami S, Linehan WM, Merino M, Chanock S, Boffetta P, Chow WH, Waldman FM, Rothman N.
Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
PLoS Genet. 7: e1002312, 2011.
127)  Rahma OE, Ashtar E, Ibrahim R, Toubaji A, Gause B, Herrin VE, Linehan WM, Steinberg SM, Grollman F, Grimes G, Bernstein SA, Berzofsky JA, Khleif SN.
A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma.
J Transl Med. 8: 8, 2010.
128)  Johann DJ, Wei BR, Prieto DA, Chan KC, Ye X, Valera VA, Simpson RM, Rudnick PA, Xiao Z, Issaq HJ, Linehan WM, Stein SE, Veenstra TD, Blonder J.
Combined blood/tissue analysis for cancer biomarker discovery: application to renal cell carcinoma.
Anal. Chem. 82: 1584-8, 2010.
129)  Mathur A, Kemp CD, Dutta U, Baid S, Ayala A, Chang RE, Steinberg SM, Papademetriou V, Lange E, Libutti SK, Pingpank JF, Alexander HR, Phan GQ, Hughes M, Linehan WM, Pinto PA, Stratakis CA, Kebebew E.
Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease.
J. Am. Coll. Surg. 211: 384-90, 2010.
130)  Miller DC, Ruterbusch J, Colt JS, Davis FG, Linehan WM, Chow WH, Schwartz K.
Contemporary clinical epidemiology of renal cell carcinoma: insight from a population based case-control study.
J. Urol. 184: 2254-8, 2010.
131)  Zhong M, De Angelo P, Osborne L, Keane-Tarchichi M, Goldfischer M, Edelmann L, Yang Y, Linehan WM, Merino MJ, Aisner S, Hameed M.
Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma.
Am. J. Surg. Pathol. 34: 757-66, 2010.
132)  Benhammou JN, Boris RS, Pacak K, Pinto PA, Linehan WM, Bratslavsky G.
Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup.
J. Urol. 184: 1855-9, 2010.
133)  Hong SB, Oh H, Valera VA, Baba M, Schmidt LS, Linehan WM.
Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization.
PLoS ONE. 5: e15793, 2010.
134)  Sourbier C, Valera-Romero V, Giubellino A, Yang Y, Sudarshan S, Neckers L, Linehan WM.
Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma.
Cell Cycle. 9: 4183-9, 2010.
135)  Bratslavsky G, Linehan WM.
Long-term management of bilateral, multifocal, recurrent renal carcinoma.
Nat Rev Urol. 7: 267-75, 2010.
136)  Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP, Srinivasan R.
Molecular diagnosis and therapy of kidney cancer.
Annu. Rev. Med. 61: 329-43, 2010.
137)  Gupta GN, Peterson J, Thakore KN, Pinto PA, Linehan WM, Bratslavsky G.
Oncological outcomes of partial nephrectomy for multifocal renal cell carcinoma greater than 4 cm.
J. Urol. 184: 59-63, 2010.
138)  Kaye DR, Storey BB, Pacak K, Pinto PA, Linehan WM, Bratslavsky G.
Partial adrenalectomy: underused first line therapy for small adrenal tumors.
J. Urol. 184: 18-25, 2010.
139)  Valera VA, Li-Ning-T E, Walter BA, Roberts DD, Linehan WM, Merino MJ.
Protein expression profiling in the spectrum of renal cell carcinomas.
J Cancer. 1: 184-96, 2010.
140)  Liu NW, Khurana K, Sudarshan S, Pinto PA, Linehan WM, Bratslavsky G.
Repeat partial nephrectomy on the solitary kidney: surgical, functional and oncological outcomes.
J. Urol. 183: 1719-24, 2010.
141)  Young LR, Vandyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, Linehan WM, Hajjar F, Kinder BW, Trapnell BC, Bissler JJ, Franz DN, McCormack FX.
Serum Vascular Endothelial Growth Factor-D Prospectively Distinguishes Lymphangioleiomyomatosis from Other Diseases.
Chest. 138(3): 674-681, 2010.
142)  Lane BR, Fergany AF, Linehan WM, Bratslavsky G.
Should preservable parenchyma, and not tumor size, be the main determinant of the feasibility of partial nephrectomy?.
Urology. 76: 608-9, 2010.
143)  Singer EA, Bratslavsky G, Linehan WM, Srinivasan R.
Targeted therapies for non-clear renal cell carcinoma.
Target Oncol. 5: 119-129, 2010.
144)  Linehan WM, Srinivasan R, Schmidt LS.
The genetic basis of kidney cancer: a metabolic disease.
Nat Rev Urol. 7: 277-85, 2010.
145)  Hong SB, Oh H, Valera VA, Stull J, Ngo DT, Baba M, Merino MJ, Linehan WM, Schmidt LS.
Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling.
Mol. Cancer. 9: 160, 2010.
146)  Yang Y, Valera VA, Padilla-Nash HM, Sourbier C, Vocke CD, Vira MA, Abu-Asab MS, Bratslavsky G, Tsokos M, Merino MJ, Pinto PA, Srinivasan R, Ried T, Neckers L, Linehan WM.
UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.
Cancer Genet. Cytogenet. 196: 45-55, 2010.
147)  Linguraru MG, Wang S, Shah F, Gautam R, Peterson J, Linehan W, Summers RM.
Computer-aided renal cancer quantification and classification from contrast-enhanced CT via histograms of curvature-related features.
Conf Proc IEEE Eng Med Biol Soc. 2009: 6679-82, 2009.
148)  Shen HC, Adem A, Ylaya K, Wilson A, He M, Lorang D, Hewitt SM, Pechhold K, Harlan DM, Lubensky IA, Schmidt LS, Linehan WM, Libutti SK.
Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations.
PLoS ONE. 4: e4897, 2009.
149)  Sudarshan S, Sourbier C, Kong H, Block K, Romero VV, Yang Y, Galindo C, Mollapour M, Scroggins B, Goode N, Lee M, Gourlay CW, Trepel J, Linehan WM, Neckers L.
Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and HIF-1{alpha} stabilization by glucose-dependent generation of reactive oxygen species.
Mol. Cell. Biol. 15: 4080-90, 2009.
150)  Linehan WM.
Genetic basis of bilateral renal cancer: implications for evaluation and management.
J. Clin. Oncol. 27: 3731-3, 2009.
151)  Linehan WM, Pinto PA, Bratslavsky G, Pfaffenroth E, Merino M, Vocke CD, Toro JR, Bottaro D, Neckers L, Schmidt LS, Srinivasan R.
Hereditary kidney cancer: unique opportunity for disease-based therapy.
Cancer. 115: 2252-61, 2009.
152)  Hasumi Y, Baba M, Ajima R, Hasumi H, Valera VA, Klein ME, Haines DC, Merino MJ, Hong SB, Yamaguchi TP, Schmidt LS, Linehan WM.
Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2.
Proc. Natl. Acad. Sci. U.S.A. 106: 18722-7, 2009.
153)  Mushinski JF, Nguyen P, Stevens LM, Khanna C, Lee S, Chung EJ, Lee MJ, Kim YS, Linehan WM, Horisberger MA, Trepel JB.
Inhibition of tumor cell motility by the interferon-inducible GTPase MxA.
J. Biol. Chem. 284: 15206-14, 2009.
154)  Boris R, Proano M, Linehan WM, Pinto PA, Bratslavsky G.
Initial experience with robot assisted partial nephrectomy for multiple renal masses.
J. Urol. 182: 1280-6, 2009.
155)  Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L.
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.
Cancer. 115: 2247-51, 2009.
156)  Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WM, Sukhatme VP, Seth P.
LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer.
Mol. Cancer Ther. 8: 626-35, 2009.
157)  Lerner SP, Bochner B, Linehan WM, Klein E, Cookson M.
Overview of SUO Winter 2008 proceedings.
Urol. Oncol. 28: 67-8, 2009.
158)  Kowalczyk KJ, Hooper HB, Linehan WM, Pinto PA, Wood BJ, Bratslavsky G.
Partial nephrectomy after previous radio frequency ablation: the National Cancer Institute experience.
J. Urol. 182: 2158-63, 2009.
159)  Grubb RL, Deng J, Pinto PA, Mohler JL, Chinnaiyan A, Rubin M, Linehan WM, Liotta LA, Petricoin EF, Wulfkuhle JD.
Pathway Biomarker Profiling of Localized and Metastatic Human Prostate Cancer Reveal Metastatic and Prognostic Signatures (dagger).
J. Proteome Res. 8: 3044-3054, 2009.
160)  Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, Sellers WR, Meyerson M, Linehan WM, Kaelin WG, Signoretti S.
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.
Cancer Res. 69: 4674-81, 2009.
161)  Linguraru MG, Yao J, Gautam R, Peterson J, Li Z, Linehan WM, Summers RM.
Renal Tumor Quantification and Classification in Contrast-Enhanced Abdominal CT.
Pattern recognition. 42: 1149-1161, 2009.
162)  Linguraru MG, Gautam R, Peterson J, Yao J, Linehan WM, Summers RM.
Proceedings / IEEE International Symposium on Biomedical Imaging: from nano to macro. IEEE International Symposium on Biomedical Imaging. 2009: 1310-1313, 2009.
163)  Giubellino A, Linehan WM, Bottaro DP.
Targeting the Met signaling pathway in renal cancer.
Expert Rev Anticancer Ther. 9: 785-93, 2009.
164)  Rosner I, Bratslavsky G, Pinto PA, Linehan WM.
The clinical implications of the genetics of renal cell carcinoma.
Urol. Oncol. 27: 131-6, 2009.
165)  Linehan WM, Rubin JS, Bottaro DP.
VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma.
Int. J. Biochem. Cell Biol. 41: 753-6, 2009.
166)  Stewart L, Glenn G, Stratton P, Goldstein A, Merino M, Tucker M.
Germline mutations in the fumarate hydratase gene confera predisposition to development of uterine fibroids.
Arch Dermatol. 2017, 2008.
In Press. [Journal]
167)  Stewart L, Glenn GM, Stratton P, Goldstein AM, Merino MJ, Tucker MA, Linehan WM, Toro JR.
Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer.
Arch Dermatol. 144: 1584-92, 2008.
168)  Toro JR, Wei M, Glenn GM, Weinreich M, Toure O, Vocke C, Turner M, Choyke P, Merino MJ, Pinto PA, Steinberg SM, Schmidt LS, Linehan WM.
BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports.
J. Med. Genet. 45: 321-31, 2008.
169)  Rogers CG, Blatt AM, Miles GE, Linehan WM, Pinto PA.
Concurrent robotic partial adrenalectomy and extra-adrenal pheochromocytoma resection in a pediatric patient with von Hippel-Lindau disease.
J. Endourol. 22: 1501-3, 2008.
170)  Eisenhofer G, Huynh TT, Elkahloun A, Morris JC, Bratslavsky G, Linehan WM, Zhuang Z, Balgley BM, Lee CS, Mannelli M, Lenders JW, Bornstein SR, Pacak K.
Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma.
Am. J. Physiol. Endocrinol. Metab. 295: E1223-33, 2008.
171)  Johnson A, Sudarshan S, Liu J, Linehan WM, Pinto PA, Bratslavsky G.
Feasibility and outcomes of repeat partial nephrectomy.
J. Urol. 180: 89-93; discussion 93, 2008.
172)  Pfaffenroth EC, Linehan WM.
Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy.
Expert opinion on biological therapy. 8: 779-90, 2008.
173)  Hasumi H, Baba M, Hong SB, Hasumi Y, Huang Y, Yao M, Valera VA, Linehan WM, Schmidt LS.
Identification and characterization of a novel folliculin-interacting protein FNIP2.
Gene. 415: 60-7, 2008.
174)  Finley DS, Narula N, Valera VA, Merino MJ, Fruehauf J, Wu ML, Linehan WM, Clayman RV.
Immunohistochemical basis for adjuvant anti-angiogenic targeted therapy for renal carcinoid: Initial case report.
Urol. Oncol. 2008.
175)  Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Mukeria A, Holcatova I, Schmidt LS, Toro JR, Karami S, Hung R, Gerard GF, Linehan WM, Merino M, Zbar B, Boffetta P, Brennan P, Rothman N, Chow WH, Waldman FM, Moore LE.
Improved identification of von hippel-lindau gene alterations in clear cell renal tumors.
Clin. Cancer Res. 14: 4726-34, 2008.
176)  Linehan WM.
Kidney cancer: Opportunity for disease specific targeted therapy.
Urol. Oncol. 26: 542, 2008.
177)  Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, Southon E, Patel V, Igarashi P, Alvord WG, Leighty R, Yao M, Bernardo M, Ileva L, Choyke P, Warren MB, Zbar B, Linehan WM, Schmidt LS.
Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.
J. Natl. Cancer Inst. 100: 140-54, 2008.
178)  Butman JA, Linehan WM, Lonser RR.
Neurologic manifestations of von Hippel-Lindau disease.
JAMA. 300: 1334-42, 2008.
179)  Rogers CG, Linehan WM, Pinto PA.
Robotic nephrectomy for kidney cancer in a horseshoe kidney with renal vein tumor thrombus: novel technique for thrombectomy.
J. Endourol. 22: 1561-3; discussion 1563, 2008.
180)  Rogers CG, Singh A, Blatt AM, Linehan WM, Pinto PA.
Robotic partial nephrectomy for complex renal tumors: surgical technique.
Eur. Urol. 53: 514-21, 2008.
181)  Rogers CG, Metwalli A, Blatt AM, Bratslavsky G, Menon M, Linehan WM, Pinto PA.
Robotic partial nephrectomy for renal hilar tumors: a multi-institutional analysis.
J. Urol. 180: 2353-6; discussion 2356, 2008.
182)  Bratslavsky G, Liu JJ, Johnson AD, Sudarshan S, Choyke PL, Linehan WM, Pinto PA.
Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes.
J. Urol. 179: 67-70, 2008.
183)  Yang Y, Padilla-Nash HM, Vira MA, Abu-Asab MS, Val D, Worrell R, Tsokos M, Merino MJ, Pavlovich CP, Ried T, Linehan WM, Vocke CD.
The UOK 257 cell line: a novel model for studies of the human Birt-Hogg-Dube gene pathway.
Cancer Genet. Cytogenet. 180: 100-9, 2008.
184)  Signoretti S, Bratslavsky G, Waldman FM, Reuter VE, Haaga J, Merino M, Thomas GV, Pins MR, Libermann T, Gillespie J, Tomaszewski JE, Compton CC, Hruszkewycz A, Linehan WM, Atkins MB.
Tissue-based research in kidney cancer: current challenges and future directions.
Clin. Cancer Res. 14: 3699-705, 2008.
185)  Lee SJ, Lattouf JB, Xanthopoulos J, Linehan WM, Bottaro DP, Vasselli JR.
Von Hippel-Lindau Tumor Suppressor Gene Loss in Renal Cell Carcinoma Promotes Oncogenic Epidermal Growth Factor Receptor Signaling via Akt-1 and MEK1.
Eur. Urol. 2008.
186)  Mai PL, Korde L, Kramer J, Peters J, Mueller CM, Pfeiffer S, Stratakis CA, Pinto PA, Bratslavsky G, Merino M, Choyke P, Linehan WM, Greene MH.
A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report.
Journal of medical case reports. 1: 9, 2007.
187)  Begnami MD, Quezado M, Pinto P, Linehan WM, Merino M.
Adenoid cystic/basal cell carcinoma of the prostate: review and update.
Arch. Pathol. Lab. Med. 131: 637-40, 2007.
188)  Srinivasan R, Linehan WM.
Antiangiogenic therapy in renal cell carcinoma: from concept to reality.
Nature clinical practice. Urology. 4: 74-5, 2007.
189)  Erickson HS, Albert PS, Gillespie JW, Wallis BS, Rodriguez-Canales J, Linehan WM, Gonzalez S, Velasco A, Chuaqui RF, Emmert-Buck MR.
Assessment of normalization strategies for quantitative RT-PCR using microdissected tissue samples.
Lab. Invest. 87: 951-62, 2007.
190)  Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, Seidel G, Shutack Y, Yuldasheva N, Eugeni M, Bartlett DL, Glenn GM, Middelton L, Linehan WM, Libutti SK.
Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs).
Surgery. 142: 814-8; discussion 818.e1-2, 2007.
191)  Catherino WH, Mayers CM, Mantzouris T, Armstrong AY, Linehan WM, Segars JH.
Compensatory alterations in energy homeostasis characterized in uterine tumors from hereditary leiomyomatosis and renal cell cancer.
Fertil Steril. 2007.
192)  Zhuang SH, Hung YE, Hung L, Robey RW, Sackett DL, Linehan WM, Bates SE, Fojo T, Poruchynsky MS.
Evidence for microtubule target engagement in tumors of patients receiving ixabepilone.
Clin. Cancer Res. 13: 7480-6, 2007.
193)  Vira M, Linehan WM.
Expanding the morphological and molecular genetic phenotype of kidney cancer.
J. Urol. 177: 10-1, 2007.
194)  Zbar B, Glenn G, Merino M, Middelton L, Peterson J, Toro J, Coleman J, Pinto P, Schmidt LS, Choyke P, Linehan WM.
Familial renal carcinoma: clinical evaluation, clinical subtypes and risk of renal carcinoma development.
J. Urol. 177: 461-5; discussion 465, 2007.
195)  Vira MA, Novakovic KR, Pinto PA, Linehan WM.
Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
BJU Int. 99: 1223-9, 2007.
196)  Wong WT, Agrón E, Coleman HR, Reed GF, Csaky K, Peterson J, Glenn G, Linehan WM, Albert P, Chew EY.
Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis.
Arch. Ophthalmol. 125: 239-45, 2007.
197)  Grubb RL, Franks ME, Toro J, Middelton L, Choyke L, Fowler S, Torres-Cabala C, Glenn GM, Choyke P, Merino MJ, Zbar B, Pinto PA, Srinivasan R, Coleman JA, Linehan WM.
Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer.
J. Urol. 177: 2074-9; discussion 2079-80, 2007.
198)  Sudarshan S, Linehan WM, Neckers L.
HIF and fumarate hydratase in renal cancer.
Br. J. Cancer. 96: 403-7, 2007.
199)  Rodriguez-Canales J, Hanson JC, Tangrea MA, Erickson HS, Albert PS, Wallis BS, Richardson AM, Pinto PA, Linehan WM, Gillespie JW, Merino MJ, Libutti SK, Woodson KG, Emmert-Buck MR, Chuaqui RF.
Identification of a unique epigenetic sub-microenvironment in prostate cancer.
J. Pathol. 211: 410-9, 2007.
200)  Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, Coleman J, Toro J, Glenn G, Vocke C, Zbar B, Schmidt LS, Bottaro D, Neckers L.
Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics.
Clin. Cancer Res. 13: 671s-679s, 2007.
201)  Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L.
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.
Clin. Cancer Res. 13: 667s-670s, 2007.
202)  Williams CR, Tabios R, Linehan WM, Neckers L.
Intratumor Injection of the Hsp90 Inhibitor 17AAG Decreases Tumor Growth and Induces Apoptosis in a Prostate Cancer Xenograft Model.
J. Urol. 178: 1528-32, 2007.
203)  Dahr SS, Cusick M, Rodriguez-Coleman H, Srivastava SK, Thompson DJ, Linehan WM, Ferris FL, Chew EY.
Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina.
Retina (Philadelphia, Pa.). 27: 150-8, 2007.
204)  Toro JR, Pautler SE, Stewart L, Glenn GM, Weinreich M, Toure O, Wei MH, Schmidt LS, Davis L, Zbar B, Choyke P, Steinberg SM, Nguyen DM, Linehan WM.
Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome.
Am. J. Respir. Crit. Care Med. 175: 1044-53, 2007.
205)  Sudarshan S, Pinto PA, Neckers L, Linehan WM.
Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer.
Nature clinical practice. Urology. 4: 104-10, 2007.
206)  Brouwers FM, Gläsker S, Nave AF, Vortmeyer AO, Lubensky I, Huang S, Abu-Asab MS, Eisenhofer G, Weil RJ, Park DM, Linehan WM, Pacak K, Zhuang Z.
Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B.
Endocr. Relat. Cancer. 14: 463-71, 2007.
207)  Bratslavsky G, Sudarshan S, Neckers L, Linehan WM.
Pseudohypoxic pathways in renal cell carcinoma.
Clin. Cancer Res. 13: 4667-71, 2007.
208)  Stone MJ, Venkatesan AM, Locklin J, Pinto P, Linehan M, Wood BJ.
Radiofrequency ablation of renal tumors.
Tech Vasc Interv Radiol. 10: 132-9, 2007.
209)  Chow WH, Linehan WM, Devesa SS.
Re: Rising incidence of small renal masses: a need to reassess treatment effect.
J. Natl. Cancer Inst. 99: 569-70; author reply 570-1, 2007.
210)  Linehan WM.
Targeting VEGF receptors in kidney cancer.
Lancet Oncol. 8: 956-7, 2007.
211)  Merino MJ, Torres-Cabala C, Pinto P, Linehan WM.
The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome.
Am. J. Surg. Pathol. 31: 1578-85, 2007.
212)  Kaji P, Carrasquillo JA, Linehan WM, Chen CC, Eisenhofer G, Pinto PA, Lai EW, Pacak K.
The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome.
Eur. J. Endocrinol. 156: 483-7, 2007.
213)  Timmers HJ, Carrasquillo JA, Whatley M, Eisenhofer G, Chen CC, Ling A, Linehan WM, Pinto PA, Adams KT, Pacak K.
Usefulness of standardized uptake values for distinguishing adrenal glands with pheochromocytoma from normal adrenal glands by use of 6-18F-fluorodopamine PET.
J. Nucl. Med. 48: 1940-4, 2007.
214)  Dhanani N, Vocke C, Bratslavsky G, Line W.
Molecular Genetics in Inherited Renal Cell Carcinoma: Identification of Targets in the Hereditary Syndromes. In: Renal Cell Carcinoma: Molecular Targets and Clinical Applications.
Humana Press; 2006. In Press. [Book Chapter]
215)  Linehan W, Coleman J, Walther M, Zbar B, Grubb RI, Choyke P, Chow W, Devesa S, Greene M, Torres-Cabala C, Kramer J, Merino M, Moore L, Potosky A.
Vogelzang N, Scardino P, Shipley W, Debruyne F, Linehan W, eds.
Comprehensive Textbook of Genitourinary Oncology.
Philadelphia: Lippincott William; 2006. [Book]
216)  Choyke P.
Vogelzang N, Scardino P, Shipley W, D F, Linehan W, eds.
Genetic Basis of Kidney Cancer. In: Comprehensive Textbook of Genitourinary Oncology.
Philadelphia: Lippincott Williams & Wilkins; 2006. p. 709-723 [Book Chapter]
217)  Linehan W, Coleman J, Walther M, Zbar B.
Vogelzang N, Scardino P, Shipley W, Debruyne F, Linehan W, eds.
Genetic Basis of Kidney Cancer. In: Comprehensive Textbook of Genitourinary Oncology.
Philadelphia: Lippincott Williams & Wilkins; 2006. p. 701-708 [Book Chapter]
218)  Lattouf JB, Arlen PM, Pinto PA, Gulley JL.
A phase I feasibility study of an intraprostatic prostate-specific antigen-based vaccine in patients with prostate cancer with local failure after radiation therapy or clinical progression on androgen-deprivation therapy in the absence of local definitive therapy.
Clinical genitourinary cancer. 5: 89-92, 2006.
219)  Srinivasan R, Daniels J, Fusaro V, Lundqvist A, Killian JK, Geho D, Quezado M, Kleiner D, Rucker S, Espina V, Whiteley G, Liotta L, Petricoin E, Pittaluga S, Hitt B, Barrett AJ, Rosenblatt K, Childs RW.
Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis.
Exp. Hematol. 34: 796-801, 2006.
220)  Athauda G, Giubellino A, Coleman JA, Horak C, Steeg PS, Lee MJ, Trepel J, Wimberly J, Sun J, Coxon A, Burgess TL, Bottaro DP.
c-Met ectodomain shedding rate correlates with malignant potential.
Clin. Cancer Res. 12: 4154-62, 2006.
221)  Riss J, Khanna C, Koo S, Chandramouli GV, Yang HH, Hu Y, Kleiner DE, Rosenwald A, Schaefer CF, Ben-Sasson SA, Yang L, Powell J, Kane DW, Star RA, Aprelikova O, Bauer K, Vasselli JR, Maranchie JK, Kohn KW, Buetow KH, Linehan WM, Weinstein JN, Lee MP, Klausner RD, Barrett JC.
Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma.
Cancer Res. 66: 7216-7224, 2006.
222)  Woldemichael GM, Vasselli JR, Gardella RS, McKee TC, Linehan WM, McMahon JB.
Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression.
Journal of biomolecular screening : the official journal of the Society for Biomolecular Screening. 11: 678-87, 2006.
223)  Linehan WM.
Editorial comment.
J. Urol. 176: 43, 2006.
224)  Kim CM, Vocke C, Torres-Cabala C, Yang Y, Schmidt L, Walther M, Linehan WM.
Expression of hypoxia inducible factor-1alpha and 2alpha in genetically distinct early renal cortical tumors.
J. Urol. 175: 1908-14, 2006.
225)  Schinstine M, Filie AC, Torres-Cabala C, Abati A, Linehan WM, Merino M.
Fine-needle aspiration of a Xp11.2 translocation/TFE3 fusion renal cell carcinoma metastatic to the lung: report of a case and review of the literature.
Diagn. Cytopathol. 34: 751-6, 2006.
226)  Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, Esposito D, Gillette WK, Hopkins RF, Hartley JL, Furihata M, Oishi S, Zhen W, Burke TR, Linehan WM, Schmidt LS, Zbar B.
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.
Proc. Natl. Acad. Sci. U.S.A. 103: 15552-7, 2006.
227)  Pithukpakorn M, Wei M, Toure O, Steinbach PJ, Glenn GM, Zbar B, Linehan WM, Toro JR.
Fumarate hydratase enzyme activity in lymphoblastoid cells and fibroblasts of individuals in families with hereditary leiomyomatosis and renal cell cancer.
J Med Genet. 43: 755-62, 2006.
228)  Brouwers FM, Elkahloun AG, Munson PJ, Eisenhofer G, Barb J, Linehan WM, Lenders JW, De Krijger R, Mannelli M, Udelsman R, Ocal IT, Shulkin BL, Bornstein SR, Breza J, Ksinantova L, Pacak K.
Gene expression profiling of benign and malignant pheochromocytoma.
Ann. N. Y. Acad. Sci. 1073: 541-56, 2006.
229)  Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM, Woodson KG.
Gene promoter methylation in prostate tumor-associated stromal cells.
J. Natl. Cancer Inst. 98: 255-61, 2006.
230)  Sudarshan S, Linehan WM.
Genetic basis of cancer of the kidney.
Semin. Oncol. 33: 544-51, 2006.
231)  Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, Pacak K.
High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing.
J. Clin. Endocrinol. Metab. 91: 4505-9, 2006.
232)  Linehan WM.
Identification of the genes for kidney cancer.
Cancer Biol. Ther. 5: 696-9, 2006.
233)  Singh AK, Ménard C, Guion P, Simone NL, Smith S, Crouse NS, Godette DJ, Cooley-Zgela T, Sciuto LC, Coleman J, Pinto P, Albert PS, Camphausen K, Coleman CN.
Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study.
Int. J. Radiat. Oncol. Biol. Phys. 65: 1008-13, 2006.
234)  Lattouf JB, Srinivasan R, Pinto PA, Linehan WM, Neckers L.
Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy.
Nature clinical practice. Urology. 3: 590-601, 2006.
235)  Jarrell ST, Vortmeyer AO, Linehan WM, Oldfield EH, Lonser RR.
Metastases to hemangioblastomas in von Hippel-Lindau disease.
J. Neurosurg. 105: 256-63, 2006.
236)  Dharmawardana PG, Peruzzi B, Giubellino A, Burke TR, Bottaro DP.
Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy.
Anticancer Drugs. 17: 13-20, 2006.
237)  Rothman A, Glenn G, Choyke L, Srinivasan R, Linehan WM, Cowen EW.
Multiple painful cutaneous nodules and renal mass.
J. Am. Acad. Dermatol. 55: 683-6, 2006.
238)  Davis IJ, Kim JJ, Ozsolak F, Widlund HR, Rozenblatt-Rosen O, Granter SR, Du J, Fletcher JA, Denny CT, Lessnick SL, Linehan WM, Kung AL, Fisher DE.
Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers.
Cancer Cell. 9: 473-84, 2006.
239)  Srinivasan R, Takahashi Y, McCoy J, Espinoza-Delgado I, Dorrance C, Igarashi T, Lundqvist A, Barrett A, Young N, Geller N, Childs R.
Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.
British Journal of Haematology. 133: 305, 2006.
240)  Peruzzi B, Bottaro DP.
Targeting the c-Met signaling pathway in cancer.
Clin. Cancer Res. 12: 3657-60, 2006.
241)  Singh SR, Zhen W, Zheng Z, Wang H, Oh SW, Liu W, Zbar B, Schmidt LS, Hou SX.
The Drosophila homolog of the human tumor suppressor gene BHD interacts with the JAK-STAT and Dpp signaling pathways in regulating male germline stem cell maintenance.
Oncogene. 25: 5933-41, 2006.
242)  Peruzzi B, Athauda G, Bottaro DP.
The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells.
Proc. Natl. Acad. Sci. U.S.A. 103: 14531-6, 2006.
243)  Huynh TT, Pacak K, Wong DL, Linehan WM, Goldstein DS, Elkahloun AG, Munson PJ, Eisenhofer G.
Transcriptional regulation of phenylethanolamine N-methyltransferase in pheochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.
Ann. N. Y. Acad. Sci. 1073: 241-52, 2006.
244)  Hong SB, Furihata M, Baba M, Zbar B, Schmidt LS.
Vascular defects and liver damage by the acute inactivation of the VHL gene during mouse embryogenesis.
Lab. Invest. 86: 664-75, 2006.
245)  Grubb RL, Linehan WM, Walther MM.
Management of Inherited Forms of Renal Cancer. In: Comprehensive Textbook of Genitourinary Oncology. Volume 3rd Edition.
Lippincott Williams & Wilkins; 2005. In Press. [Book Chapter]
246)  Grubb RL, Walther MM, Linehan WM.
The Genetic Basis of Cancer of the Kidney. In: Genetic Diseases of the Kidney.
San Diego: Elsevier Inc; 2005. In Press. [Book Chapter]
247)  Linehan W, Yang J, Bates S.
DeVita S, Hellman S, Rosenberg S, eds.
Cancer of the Kidney. In: Cancer Principles & Practice of Oncology.
Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1139-1168 [Book Chapter]
248)  Shi Z, Peruzzi B, Dharmawardana P, Leech T, Appella E, Worthy K, Bindu L, Fisher R, Bottaro D, Burke TJ.
Synthesis and use of C-terminally biotinylated peptidomimetics with high Grb2 SH2 domain-binding affinity. In: Understanding Biology Using Peptides.
La Costa: American Peptide Society; 2005. p. 208-209 [Book Chapter]
249)  Lee YS, Vortmeyer AO, Lubensky IA, Vogel TW, Ikejiri B, Ferlicot S, Benoît G, Giraud S, Oldfield EH, Linehan WM, Teh BT, Richard S, Zhuang Z.
Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma.
Clin Cancer Res. 11: 1059-64, 2005.
250)  Huynh TT, Pacak K, Brouwers FM, Abu-Asab MS, Worrell RA, Walther MM, Elkahloun AG, Goldstein DS, Cleary S, Eisenhofer G.
Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.
Eur. J. Endocrinol. 153: 551-63, 2005.
251)  Vogel TW, Brouwers FM, Lubensky IA, Vortmeyer AO, Weil RJ, Walther MM, Oldfield EH, Linehan WM, Pacak K, Zhuang Z.
Differential expression of erythropoietin and its receptor in von hippel-lindau-associated and multiple endocrine neoplasia type 2-associated pheochromocytomas.
J Clin Endocrinol Metab. 90: 3747-51, 2005.
252)  Gorak E, Geller N, Srinivasan R, Espinoza-Delgado I, Donohue T, Barrett A, Suffredini A, Childs R.
Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival.
Biology of Blood and Marrow Transplantation. 11: 542-550, 2005.
253)  Pavlovich CP, Grubb RL, Hurley K, Glenn GM, Toro J, Schmidt LS, Torres-Cabala C, Merino MJ, Zbar B, Choyke P, Walther MM, Linehan WM.
Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome.
J Urol. 173: 1482-6, 2005.
254)  Kang SU, Shi ZD, Worthy KM, Bindu LK, Dharmawardana PG, Choyke SJ, Bottaro DP, Fisher RJ, Burke TR.
Examination of phosphoryl-mimicking functionalities within a macrocyclic Grb2 SH2 domain-binding platform.
J. Med. Chem. 48: 3945-8, 2005.
255)  Schmidt LS, Nickerson ML, Warren MB, Glenn GM, Toro JR, Merino MJ, Turner ML, Choyke PL, Sharma N, Peterson J, Morrison P, Maher ER, Walther MM, Zbar B, Linehan WM.
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome.
Am J Hum Genet. 76: 1023-33, 2005.
256)  Matyakhina L, Freedman RJ, Bourdeau I, Wei MH, Stergiopoulos SG, Chidakel A, Walther M, Abu-Asab M, Tsokos M, Keil M, Toro J, Linehan WM, Stratakis CA.
Hereditary leiomyomatosis associated with bilateral, massive, macronodular adrenocortical disease and atypical cushing syndrome: a clinical and molecular genetic investigation.
J Clin Endocrinol Metab. 90: 3773-9, 2005.
257)  Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, Neckers L.
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability.
Cancer Cell. 8: 143-53, 2005.
258)  Vocke CD, Yang Y, Pavlovich CP, Schmidt LS, Nickerson ML, Torres-Cabala CA, Merino MJ, Walther MM, Zbar B, Linehan WM.
High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dube-associated renal tumors.
J Natl Cancer Inst. 97: 931-5, 2005.
259)  Childs R, Srinivasan R.
High-dose chemotherapy and allogeneic immunotherapy.
The Lancet. 366: 273-275, 2005.
260)  Coleman J, Franks ME, Grubb RL, Wynberg J, Lee CS, Behari A, Kim CM, Williams C, Linehan WM.
Highlights from the Society of Urologic Oncology 4th annual meeting.
J Urol. 173: 938-41, 2005.
261)  Grubb RL, Behari A, Kim CM, Williams CR, Linehan WM, Coleman JA.
Highlights from the Society of Urologic Oncology, 5th Annual Meeting, December 3-4, 2004, Bethesda, Maryland, United States of America.
J. Urol. 174: 2330-3, 2005.
262)  Gannot G, Gillespie JW, Chuaqui RF, Tangrea MA, Linehan WM, Emmert-Buck MR.
Histomathematical analysis of clinical specimens: challenges and progress.
J Histochem Cytochem. 53: 177-85, 2005.
263)  Grubb RL, Choyke PL, Pinto PA, Linehan WM, Walther MM.
Management of von Hippel-Lindau-associated kidney cancer.
Nat Clin Pract Urol. 2: 248-55, 2005.
264)  Diner EK, Williams CR, Behari A, Pinto PA, Linehan WM, Walther MM.
Metastatic renal cell carcinoma to contralateral ureter presenting as acute obstructive renal failure after radical nephrectomy.
Urology. 65: 1001, 2005.
265)  Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, González S, Velasco A, Linehan WM, Matusik RJ, Price DK, Figg WD, Emmert-Buck MR, Chuaqui RF.
Molecular Alterations in Primary Prostate Cancer after Androgen Ablation.
Clin Cancer Res. 11: 6823-34, 2005.
266)  Bottaro DP, Linehan WM.
Multifocal renal cancer: genetic basis and its medical relevance.
Clin Cancer Res. 11: 7206-8, 2005.
267)  Srinivasan R, Balow J, Sabnis S, Lundqvist A, Igarashi T, Takahashi Y, Austin H, Tisdale J, Barrett J, Geller N, Childs R.
Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation.
British Journal of Haematology. 131(1): 74-, 2005.
268)  Wei MH, Toure O, Glenn GM, Pithukpakorn M, Neckers L, Stolle C, Choyke P, Grubb R, Middelton L, Turner ML, Walther MM, Merino MJ, Zbar B, Linehan WM, Toro JR.
Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer.
J Med Genet. 2005.
269)  Warburton HE, Brady M, Vlatkovic N, Linehan WM, Parsons K, Boyd MT.
p53 regulation and function in renal cell carcinoma.
Cancer Res. 65: 6498-503, 2005.
270)  Diner EK, Franks ME, Behari A, Linehan WM, Walther MM.
Partial adrenalectomy: the National Cancer Institute experience.
Urology. 66: 19-23, 2005.
271)  Griffith L, McCoy J, Bolan C, Stroncek D, Pickett A, Linton G, Lundqvist A, Srinivasan R, Leitman S, Childs R.
Persistence of recipient plasma cells and anti-donor hemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible nonmyeloablative hematopoietic cell transplantation.
British Journal of Haematology. 128: 668-, 2005.
272)  Srinivasan R, Filie A, Reynolds J, Chang R, Chow C, Schrump D, Takahashi Y, Suffredini A, Childs R.
Positron emission tomography for lymphoma staging: tissue remains the issue.
J Natl Cancer Inst. 97(8): 611-3, 2005.
273)  Diner EK, Linehan M, Walther M.
Response of papillary renal cell carcinoma in a solitary kidney to high dose interleukin therapy.
International journal of urology : official journal of the Japanese Urological Association. 12: 996-7, 2005.
274)  Srinivasan R, Linehan WM.
Targeted for destruction: the molecular basis for development of novel therapeutic strategies in renal cell cancer.
J Clin Oncol. 23: 410-2, 2005.
275)  Linehan WM, Grubb RL, Coleman JA, Zbar B, Walther MM.
The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management.
BJU Int. 95 Suppl 2: 2-7, 2005.
276)  Beppu K, Nakamura K, Linehan WM, Rapisarda A, Thiele CJ.
Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
Cancer Res. 65: 4775-81, 2005.
277)  Savani B, Srinivasan R, Espinosa-Delgado I, Dorrance C, Takahashi Y, Igarashi T, Rezvani K, Lundqvist A, Barrett A, Childs R.
Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib.
The Lancet Oncology. 6: 809-812, 2005.
278)  Shi ZD, Karki RG, Oishi S, Worthy KM, Bindu LK, Dharmawardana PG, Nicklaus MC, Bottaro DP, Fisher RJ, Burke TR.
Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic.
Bioorg. Med. Chem. Lett. 15: 1385-8, 2005.
279)  Stoyanova R, Clapper ML, Bellacosa A, Henske EP, Testa JR, Ross EA, Yeung AT, Nicolas E, Tsichlis N, Li YS, Linehan WM, Howard S, Campbell KS, Godwin AK, Boman BM, Crowell JA, Kopelovich L, Knudson AG.
Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations.
Cancer Biol Ther. 3: 1313-21, 2004.
280)  Weeks DC, Walther MM, Stratakis CA, Hwang JJ, Linehan WM, Phillips JL.
Bilateral testicular adrenal rests after bilateral adrenalectomies in a cushingoid patient with von Hippel-Lindau disease.
Urology. 63: 981-2, 2004.
281)  Perlmutter MA, Best CJ, Gillespie JW, Gathright Y, González S, Velasco A, Linehan WM, Emmert-Buck MR, Chuaqui RF.
Comparison of snap freezing versus ethanol fixation for gene expression profiling of tissue specimens.
J Mol Diagn. 6: 371-7, 2004.
282)  Eisenhofer G, Huynh TT, Pacak K, Brouwers FM, Walther MM, Linehan WM, Munson PJ, Mannelli M, Goldstein DS, Elkahloun AG.
Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome.
Endocr Relat Cancer. 11: 897-911, 2004.
283)  Schmidt LS, Nickerson ML, Angeloni D, Glenn GM, Walther MM, Albert PS, Warren MB, Choyke PL, Torres-Cabala CA, Merino MJ, Brunet J, Bérez V, Borràs J, Sesia G, Middelton L, Phillips JL, Stolle C, Zbar B, Pautler SE, Linehan WM.
Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene.
J Urol. 172: 1256-61, 2004.
284)  .
Editorial comment.
Urology. 64: 368, 2004.
285)  Choo D, Shotland L, Mastroianni M, Glenn G, van Waes C, Linehan WM, Oldfield EH.
Endolymphatic sac tumors in von Hippel-Lindau disease.
J Neurosurg. 100: 480-7, 2004.
286)  Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW.
Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
Blood. 104: 170-7, 2004.
287)  Tangrea MA, Chuaqui RF, Gillespie JW, Ahram M, Gannot G, Wallis BS, Best CJ, Linehan WM, Liotta LA, Pohida TJ, Bonner RF, Emmert-Buck MR.
Expression microdissection: operator-independent retrieval of cells for molecular profiling.
Diagn Mol Pathol. 13: 207-12, 2004.
288)  Warren MB, Torres-Cabala CA, Turner ML, Merino MJ, Matrosova VY, Nickerson ML, Ma W, Linehan WM, Zbar B, Schmidt LS.
Expression of Birt-Hogg-Dube gene mRNA in normal and neoplastic human tissues.
Mod Pathol. 17: 998-1011, 2004.
289)  Linehan WM, Zbar B.
Focus on kidney cancer.
Cancer Cell. 6: 223-8, 2004.
290)  Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, Vocke C, Schmidt L, Isaacs JS, Glenn G, Toro J, Zbar B, Bottaro D, Neckers L.
Genetic basis of cancer of the kidney: disease-specific approaches to therapy.
Clin Cancer Res. 10: 6282S-9S, 2004.
291)  Figg WD, Franks ME, Venzon D, Duray P, Cox MC, Linehan WM, Van Bingham W, Eastham JA, Reed E, Sartor O.
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer.
World J Urol. 22: 425-30, 2004.
292)  Woodson K, Gillespie J, Hanson J, Emmert-Buck M, Phillips JM, Linehan WM, Tangrea JA.
Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: a histopathologic study of whole mount prostate specimens.
Prostate. 60: 25-31, 2004.
293)  Oh S, Terabe M, Pendleton CD, Bhattacharyya A, Bera TK, Epel M, Reiter Y, Phillips J, Linehan WM, Kasten-Sportes C, Pastan I, Berzofsky JA.
Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.
Cancer Res. 64: 2610-8, 2004.
294)  Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L.
Innovations and challenges in renal cancer: consensus statement from the first international conference.
Clin Cancer Res. 10: 6277S-81S, 2004.
295)  Hwang J, Shoaf G, Uchio EM, Watson J, Pacak K, Linehan WM, Walther MM.
Laparoscopic management of extra-adrenal pheochromocytoma.
J Urol. 171: 72-6, 2004.
296)  Zeeberg BR, Riss J, Kane DW, Bussey KJ, Uchio E, Linehan WM, Barrett JC, Weinstein JN.
Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics.
BMC Bioinformatics. 5: 80, 2004.
297)  Drachenberg DE, Mena OJ, Choyke PL, Linehan WM, Walther MM.
Parenchymal sparing surgery for central renal tumors in patients with hereditary renal cancers.
J Urol. 172: 49-53, 2004.
298)  Carvallo C, Geller N, Kurlander R, Srinivasan R, Mena O, Igarashi T, Griffith LM, Linehan WM, Childs RW.
Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors.
Blood. 103: 1560-3, 2004.
299)  Hwang JJ, Walther MM, Pautler SE, Coleman JA, Hvizda J, Peterson J, Linehan WM, Wood BJ.
Radio frequency ablation of small renal tumors:: intermediate results.
J Urol. 171: 1814-8, 2004.
300)  Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD.
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
J Clin Oncol. 22: 2532-9, 2004.
301)  Aprelikova O, Chandramouli GV, Wood M, Vasselli JR, Riss J, Maranchie JK, Linehan WM, Barrett JC.
Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors.
J Cell Biochem. 92: 491-501, 2004.
302)  Stevens J, Nichelson E, Linehan WM, Thompson N, Liewehr D, Venzon D, Walther MM.
Risk factors for skin breakdown after renal and adrenal surgery.
Urology. 64: 246-9, 2004.
303)  Loaiza-Pérez AI, Kenney S, Boswell J, Hollingshead M, Hose C, Linehan WM, Worrell R, Rubinstein L, Sausville EA, Vistica DT.
Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1.
J Urol. 171: 1688-97, 2004.
304)  Maranchie JK, Afonso A, Albert PS, Kalyandrug S, Phillips JL, Zhou S, Peterson J, Ghadimi BM, Hurley K, Riss J, Vasselli JR, Ried T, Zbar B, Choyke P, Walther MM, Klausner RD, Linehan WM.
Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location.
Hum Mutat. 23: 40-6, 2004.
305)  Alleman WG, Tabios RL, Chandramouli GV, Aprelikova ON, Torres-Cabala C, Mendoza A, Rogers C, Rodgers C, Sopko NA, Linehan WM, Vasselli JR.
The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine.
Clin Cancer Res. 10: 7011-21, 2004.
306)  Duffey BG, Choyke PL, Glenn G, Grubb RL, Venzon D, Linehan WM, Walther MM.
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease.
J Urol. 172: 63-5, 2004.
307)  Uchio EM, Linehan WM, Figg WD, Walther MM.
A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder.
J. Urol. 169: 357-60, 2003.
308)  Drachenberg D, Childs RW.
Allogeneic stem cell transplantation as immunotherapy for renal cell carcinoma: from immune enhancement to immune replacement.
Urol Clin North Am. 30: 611-22, 2003.
309)  Bottaro DP, Liotta LA.
Cancer: Out of air is not out of action.
Nature. 423: 593-5, 2003.
310)  Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W.
Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.
Nature. 425: 307-11, 2003.
311)  Kim IY, Lee DH, Lee DK, Kim BC, Kim HT, Leach FS, Linehan WM, Morton RA, Kim SJ.
Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells.
Clin Cancer Res. 9: 6046-51, 2003.
312)  Hwang JJ, Uchio EM, Patel SV, Linehan WM, Walther MM, Pacak K.
Diagnostic localization of malignant bladder pheochromocytoma using 6-18F fluorodopamine positron emission tomography.
J. Urol. 169: 274-5, 2003.
313)  Ahram M, Flaig MJ, Gillespie JW, Duray PH, Linehan WM, Ornstein DK, Niu S, Zhao Y, Petricoin EF, Emmert-Buck MR.
Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications.
Proteomics. 3: 413-21, 2003.
314)  Toro JR, Glenn G, Hou L, Duray P, Clark B, Merino M, Zbar B, Linehan M, Turner ML.
Facial papules, spontaneous pneumothorax, and renal tumors.
J. Am. Acad. Dermatol. 48: 111-4, 2003.
315)  Maranchie JK, Linehan WM.
Genetic disorders and renal cell carcinoma.
Urol Clin North Am. 30: 133-41, 2003.
316)  Hwang JJ, Uchio EM, Linehan WM, Walther MM.
Hereditary kidney cancer.
Urol Clin North Am. 30: 831-42, 2003.
317)  Choyke PL, Glenn GM, Walther MM, Zbar B, Linehan WM.
Hereditary renal cancers.
Radiology. 226: 33-46, 2003.
318)  Barrett JC, Bennett LM, Fleming LK, Linehan WM, Liotta LA, Rosenberg SA, Petricoin EF, Staudt LM, Thompson TE, Yang JC.
Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research.
Clinical advances in hematology & oncology : H&O. 1: 302-6, 2003.
319)  Yacoub A, Mitchell C, Brannon J, Rosenberg E, Qiao L, McKinstry R, Linehan WM, Su ZS, Sarkar D, Lebedeva IV, Valerie K, Gopalkrishnan RV, Grant S, Fisher PB, Dent P.
MDA-7 (interleukin-24) inhibits the proliferation of renal carcinoma cells and interacts with free radicals to promote cell death and loss of reproductive capacity.
Mol. Cancer Ther. 2: 623-32, 2003.
320)  Best CJ, Leiva IM, Chuaqui RF, Gillespie JW, Duray PH, Murgai M, Zhao Y, Simon R, Kang JJ, Green JE, Bostwick DG, Linehan WM, Emmert-Buck MR.
Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis.
Diagn Mol Pathol. 12: 63-70, 2003.
321)  Linehan WM.
Molecular targeting of VHL gene pathway in clear cell kidney cancer.
J Urol. 170: 593-4, 2003.
322)  Linehan WM.
Molecular targeting of VHL gene pathway in clear cell kidney cancer.
J Urol. 170: 593-4, 2003.
323)  Toro JR, Nickerson ML, Wei MH, Warren MB, Glenn GM, Turner ML, Stewart L, Duray P, Tourre O, Sharma N, Choyke P, Stratton P, Merino M, Walther MM, Linehan WM, Schmidt LS, Zbar B.
Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.
Am J Hum Genet. 73: 95-106, 2003.
324)  Toro JR, Nickerson ML, Wei MH, Warren MB, Glenn GM, Turner ML, Stewart L, Duray P, Tourre O, Sharma N, Choyke P, Stratton P, Merino M, Walther MM, Linehan WM, Schmidt LS, Zbar B.
Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.
Am J Hum Genet. 73: 95-106, 2003.
325)  Pavlovich CP, Padilla-Nash H, Wangsa D, Nickerson ML, Matrosova V, Linehan WM, Ried T, Phillips JL.
Patterns of aneuploidy in stage IV clear cell renal cell carcinoma revealed by comparative genomic hybridization and spectral karyotyping.
Genes Chromosomes Cancer. 37: 252-60, 2003.
326)  Vasselli JR, Shih JH, Iyengar SR, Maranchie J, Riss J, Worrell R, Torres-Cabala C, Tabios R, Mariotti A, Stearman R, Merino M, Walther MM, Simon R, Klausner RD, Linehan WM.
Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor.
Proc. Natl. Acad. Sci. U.S.A. 100: 6958-63, 2003.
327)  Carvallo C, Geller N, Kurlander R, Srinivasan R, Mena O, Igarashi T, Griffith LM, Linehan WM, Childs RW.
Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in solid tumor patients.
Blood. 2003.
328)  Hwang JJ, Dharmawardana PG, Uchio EM, Wynberg J, Phillips JL.
Prostate cancer in Klinefelter syndrome during hormonal replacement therapy.
Urology. 62: 941, 2003.
329)  Grubb RL, Calvert VS, Wulkuhle JD, Paweletz CP, Linehan WM, Phillips JL, Chuaqui R, Valasco A, Gillespie J, Emmert-Buck M, Liotta LA, Petricoin EF.
Signal pathway profiling of prostate cancer using reverse phase protein arrays.
Proteomics. 3: 2142-6, 2003.
330)  Zbar B, Klausner R, Linehan WM.
Studying cancer families to identify kidney cancer genes.
Annu. Rev. Med. 54: 217-33, 2003.
331)  Hwang JJ, Uchio EM, Pavlovich CP, Pautler SE, Libutti SK, Linehan WM, Walther MM.
Surgical management of multi-organ visceral tumors in patients with von Hippel-Lindau disease: a single stage approach.
J Urol. 169: 895-8, 2003.
332)  Linehan WM, Walther MM, Zbar B.
The genetic basis of cancer of the kidney.
J Urol. 170: 2163-72, 2003.
333)  Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH.
von Hippel-Lindau disease.
Lancet. 361: 2059-67, 2003.
334)  Pautler SE, Harrington FS, McWilliams GW, Walther MM.
A novel laparoscopic specimen entrapment device to facilitate morcellation of large renal tumors.
Urology. 59: 591-3, 2002.
335)  Pautler SE, Phillips JL, Walther MM.
Assessment of risk for intra-abdominal adhesions at laparoscopy for urological tumors.
J. Urol. 168: 2391-4, 2002.
336)  Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, Eisenhofer G.
Biochemical diagnosis of pheochromocytoma: which test is best?.
JAMA. 287: 1427-34, 2002.
337)  Swalwell JI, Vocke CD, Yang Y, Walker JR, Grouse L, Myers SH, Gillespie JW, Bostwick DG, Duray PH, Linehan WM, Emmert-Buck MR.
Determination of a minimal deletion interval on chromosome band 8p21 in sporadic prostate cancer.
Genes Chromosomes Cancer. 33: 201-5, 2002.
338)  Bodmer D, Eleveld M, Kater-Baats E, Janssen I, Janssen B, Weterman M, Schoenmakers E, Nickerson M, Linehan M, Zbar B, van Kessel AG.
Disruption of a novel MFS transporter gene, DIRC2, by a familial renal cell carcinoma-associated t(2;3)(q35;q21).
Hum. Mol. Genet. 11: 641-9, 2002.
339)  Linehan WM.
Editorial: Kidney cancer--a unique opportunity for the development of disease specific therapy.
J. Urol. 168: 2411-2, 2002.
340)  Gillespie JW, Best CJ, Bichsel VE, Cole KA, Greenhut SF, Hewitt SM, Ahram M, Gathright YB, Merino MJ, Strausberg RL, Epstein JI, Hamilton SR, Gannot G, Baibakova GV, Calvert VS, Flaig MJ, Chuaqui RF, Herring JC, Pfeifer J, Petricoin EF, Linehan WM, Duray PH, Bova GS, Emmert-Buck MR.
Evaluation of non-formalin tissue fixation for molecular profiling studies.
Am. J. Pathol. 160: 449-57, 2002.
341)  Pautler SE, Richards C, Libutti SK, Linehan WM, Walther MM.
Intentional resection of the diaphragm during cytoreductive laparoscopic radical nephrectomy.
J. Urol. 167: 48-50, 2002.
342)  Pautler SE, Choyke PL, Pavlovich CP, Daryanani K, Walther MM.
Intraoperative ultrasound aids in dissection during laparoscopic partial adrenalectomy.
J. Urol. 168: 1352-5, 2002.
343)  Pautler SE, Walther MM.
Laparoscopic radical nephrectomy for advanced kidney cancer.
Current urology reports. 3: 21-4, 2002.
344)  Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML, Duray P, Merino M, Choyke P, Pavlovich CP, Sharma N, Walther M, Munroe D, Hill R, Maher E, Greenberg C, Lerman MI, Linehan WM, Zbar B, Schmidt LS.
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome.
Cancer Cell. 2: 157-64, 2002.
345)  Marcos HB, Libutti SK, Alexander HR, Lubensky IA, Bartlett DL, Walther MM, Linehan WM, Glenn GM, Choyke PL.
Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison.
Radiology. 225: 751-8, 2002.
346)  Pavlovich CP, Walther MM, Choyke PL, Pautler SE, Chang R, Linehan WM, Wood BJ.
Percutaneous radio frequency ablation of small renal tumors: initial results.
J. Urol. 167: 10-5, 2002.
347)  Koch CA, Mauro D, Walther MM, Linehan WM, Vortmeyer AO, Jaffe R, Pacak K, Chrousos GP, Zhuang Z, Lubensky IA.
Pheochromocytoma in von hippel-lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2.
Endocr. Pathol. 13: 17-27, 2002.
348)  Chuaqui RF, Bonner RF, Best CJ, Gillespie JW, Flaig MJ, Hewitt SM, Phillips JL, Krizman DB, Tangrea MA, Ahram M, Linehan WM, Knezevic V, Emmert-Buck MR.
Post-analysis follow-up and validation of microarray experiments.
Nat. Genet. 32 Suppl: 509-14, 2002.
349)  Feldman AL, Alexander HR, Yang JC, Linehan WM, Eyler RA, Miller MS, Steinberg SM, Libutti SK.
Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma.
Cancer. 95: 1637-43, 2002.
350)  Ahram M, Best CJ, Flaig MJ, Gillespie JW, Leiva IM, Chuaqui RF, Zhou G, Shu H, Duray PH, Linehan WM, Raffeld M, Ornstein DK, Zhao Y, Petricoin EF, Emmert-Buck MR.
Proteomic analysis of human prostate cancer.
Mol. Carcinog. 33: 9-15, 2002.
351)  Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, Linehan WM, Merino MJ.
Renal tumors in the Birt-Hogg-Dubé syndrome.
Am. J. Surg. Pathol. 26: 1542-52, 2002.
352)  Zbar B, Alvord WG, Glenn G, Turner M, Pavlovich CP, Schmidt L, Walther M, Choyke P, Weirich G, Hewitt SM, Duray P, Gabril F, Greenberg C, Merino MJ, Toro J, Linehan WM.
Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome.
Cancer Epidemiol. Biomarkers Prev. 11: 393-400, 2002.
353)  Caldwell MC, Hough C, Fürer S, Linehan WM, Morin PJ, Gorospe M.
Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNFalpha cytotoxicity.
Oncogene. 21: 929-36, 2002.
354)  Petricoin EF, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC, Liotta LA.
Serum proteomic patterns for detection of prostate cancer.
J. Natl. Cancer Inst. 94: 1576-8, 2002.
355)  Pautler SE, Hewitt SM, Linehan WM, Walther MM.
Specimen morcellation after laparoscopic radical nephrectomy: confirmation of histologic diagnosis using needle biopsy.
J. Endourol. 16: 89-92, 2002.
356)  Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD.
The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma.
Cancer Cell. 1: 247-55, 2002.
357)  Kuzmin I, Gillespie JW, Protopopov A, Geil L, Dreijerink K, Yang Y, Vocke CD, Duh FM, Zabarovsky E, Minna JD, Rhim JS, Emmert-Buck MR, Linehan WM, Lerman MI.
The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells.
Cancer Res. 62: 3498-502, 2002.
358)  Pautler SE, Walther MM.
Transperitoneal laparoscopic radical nephrectomy for bulky renal tumors.
The Canadian journal of urology. 9: 1653-9; discussion 1660, 2002.
359)  Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner RD.
VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.
Cancer Res. 62: 3014-9, 2002.
360)  Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL.
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
Semin. Oncol. 28: 62-6, 2001.
361)  Pavlovich CP, Battiwalla M, Rick ME, Walther MM.
Antibody induced coagulopathy from bovine thrombin use during partial nephrectomy.
J. Urol. 165: 1617, 2001.
362)  Schmidt LS, Warren MB, Nickerson ML, Weirich G, Matrosova V, Toro JR, Turner ML, Duray P, Merino M, Hewitt S, Pavlovich CP, Glenn G, Greenberg CR, Linehan WM, Zbar B.
Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2.
Am. J. Hum. Genet. 69: 876-82, 2001.
363)  McNeil DE, Linehan WM, Glenn GM.
Comorbid genetic diseases, von Hippel-Lindau disease and spinocerebellar ataxia type 2, confounding the diagnosis of cerebellar dysfunction in an adolescent.
Clinical neurology and neurosurgery. 103: 216-9, 2001.
364)  Maranchie JK, Walther MM.
Early identification of patients with von Hippel-Lindau disease at risk for pheochromocytoma.
Current urology reports. 2: 24-30, 2001.
365)  Ornstein DK, Cinquanta M, Weiler S, Duray PH, Emmert-Buck MR, Vocke CD, Linehan WM, Ferretti JA.
Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium.
J. Urol. 165: 1329-34, 2001.
366)  Choyke PL, Pavlovich CP, Daryanani KD, Hewitt SM, Linehan WM, Walther MM.
Intraoperative ultrasound during renal parenchymal sparing surgery for hereditary renal cancers: a 10-year experience.
J. Urol. 165: 397-400, 2001.
367)  Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM.
Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
J. Urol. 166: 68-72, 2001.
368)  Phillips JL, Ghadimi BM, Wangsa D, Padilla-Nash H, Worrell R, Hewitt S, Walther M, Linehan WM, Klausner RD, Ried T.
Molecular cytogenetic characterization of early and late renal cell carcinomas in von Hippel-Lindau disease.
Genes Chromosomes Cancer. 31: 1-9, 2001.
369)  Chernoff A, Choyke PL, Linehan WM, Walther MM.
Parenchymal sparing surgery in a patient with multiple bilateral papillary renal cancer.
J. Urol. 165: 1623-4, 2001.
370)  Herring JC, Enquist EG, Chernoff A, Linehan WM, Choyke PL, Walther MM.
Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience.
J. Urol. 165: 777-81, 2001.
371)  Pavlovich CP, Linehan WM, Walther MM.
Partial adrenalectomy in patients with multiple adrenal tumors.
Current urology reports. 2: 19-23, 2001.
372)  Eisenhofer G, Walther MM, Huynh TT, Li ST, Bornstein SR, Vortmeyer A, Mannelli M, Goldstein DS, Linehan WM, Lenders JW, Pacak K.
Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes.
J. Clin. Endocrinol. Metab. 86: 1999-2008, 2001.
373)  Lei JY, Middleton LP, Guo XD, Duray PH, McWilliams G, Linehan WM, Merino MJ.
Pigmented renal clear cell carcinoma with melanocytic differentiation.
Hum. Pathol. 32: 233-6, 2001.
374)  Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS.
Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma.
Ann. Intern. Med. 134: 315-29, 2001.
375)  Pautler SE, Pavlovich CP, Mikityansky I, Drachenberg DE, Choyke PL, Linehan WM, Wood BJ, Walther MM.
Retroperitoneoscopic-guided radiofrequency ablation of renal tumors.
The Canadian journal of urology. 8: 1330-3, 2001.
376)  Mertins SD, Myers TG, Hollingshead M, Dykes D, Bodde E, Tsai P, Jefferis CA, Gupta R, Linehan WM, Alley M, Bates SE.
Screening for and identification of novel agents directed at renal cell carcinoma.
Clin. Cancer Res. 7: 620-33, 2001.
377)  Phillips JL, Hayward SW, Wang Y, Vasselli J, Pavlovich C, Padilla-Nash H, Pezullo JR, Ghadimi BM, Grossfeld GD, Rivera A, Linehan WM, Cunha GR, Ried T.
The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis.
Cancer Res. 61: 8143-9, 2001.
378)  Phillips JL, Pavlovich CP, Walther M, Ried T, Linehan WM.
The genetic basis of renal epithelial tumors: advances in research and its impact on prognosis and therapy.
Current opinion in urology. 11: 463-9, 2001.
379)  Walther MC, Shawker TH, Libutti SK, Lubensky I, Choyke PL, Venzon D, Linehan WM.
A phase 2 study of radio frequency interstitial tissue ablation of localized renal tumors.
J. Urol. 163: 1424-7, 2000.
380)  Ornstein DK, Englert C, Gillespie JW, Paweletz CP, Linehan WM, Emmert-Buck MR, Petricoin EF.
Characterization of intracellular prostate-specific antigen from laser capture microdissected benign and malignant prostatic epithelium.
Clin. Cancer Res. 6: 353-6, 2000.
381)  Libutti SK, Choyke PL, Alexander HR, Glenn G, Bartlett DL, Zbar B, Lubensky I, McKee SA, Maher ER, Linehan WM, Walther MM.
Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease.
Surgery. 128: 1022-7;discussion 1027-8, 2000.
382)  Carlisle AJ, Prabhu VV, Elkahloun A, Hudson J, Trent JM, Linehan WM, Williams ED, Emmert-Buck MR, Liotta LA, Munson PJ, Krizman DB.
Development of a prostate cDNA microarray and statistical gene expression analysis package.
Mol. Carcinog. 28: 12-22, 2000.
383)  Mohr VH, Vortmeyer AO, Zhuang Z, Libutti SK, Walther MM, Choyke PL, Zbar B, Linehan WM, Lubensky IA.
Histopathology and molecular genetics of multiple cysts and microcystic (serous) adenomas of the pancreas in von Hippel-Lindau patients.
Am. J. Pathol. 157: 1615-21, 2000.
384)  Walther MM, Herring J, Choyke PL, Linehan WM.
Laparoscopic partial adrenalectomy in patients with hereditary forms of pheochromocytoma.
J. Urol. 164: 14-7, 2000.
385)  Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS, Vocke CD, Hewitt SM, Duray PH, Herring J, Wang QH, Hu N, Linehan WM, Taylor PR, Liotta LA, Emmert-Buck MR, Petricoin EF.
Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma.
Cancer Res. 60: 6293-7, 2000.
386)  Linehan WM.
Molecular genetics of kidney cancer: implications for the physician.
Proceedings (Baylor University. Medical Center). 13: 368-71, 2000.
387)  Emmert-Buck MR, Strausberg RL, Krizman DB, Bonaldo MF, Bonner RF, Bostwick DG, Brown MR, Buetow KH, Chuaqui RF, Cole KA, Duray PH, Englert CR, Gillespie JW, Greenhut S, Grouse L, Hillier LW, Katz KS, Klausner RD, Kuznetzov V, Lash AE, Lennon G, Linehan WM, Liotta LA, Marra MA, Munson PJ, Ornstein DK, Prabhu VV, Prang C, Schuler GD, Soares MB, Tolstoshev CM, Vocke CD, Waterston RH.
Molecular profiling of clinical tissues specimens: feasibility and applications.
The Journal of molecular diagnostics : JMD. 2: 60-6, 2000.
388)  Sgambati MT, Stolle C, Choyke PL, Walther MM, Zbar B, Linehan WM, Glenn GM.
Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents.
Am. J. Hum. Genet. 66: 84-91, 2000.
389)  Phillips JL, Walther MM, Pezzullo JC, Rayford W, Choyke PL, Berman AA, Linehan WM, Doppman JL, Gill Jr JR.
Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma.
J. Clin. Endocrinol. Metab. 85: 4526-33, 2000.
390)  Ornstein DK, Lubensky IA, Venzon D, Zbar B, Linehan WM, Walther MM.
Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer.
J. Urol. 163: 431-3, 2000.
391)  Linehan WM.
Prostate cancer: where are we going?.
Proceedings (Baylor University. Medical Center). 13: 366-7, 2000.
392)  Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, Topalian SL, Bostwick DG, Linehan WM, Petricoin EF, Emmert-Buck MR.
Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines.
Electrophoresis. 21: 2235-42, 2000.
393)  Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ.
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
N. Engl. J. Med. 343: 750-8, 2000.
394)  Feldman AL, Tamarkin L, Paciotti GF, Simpson BW, Linehan WM, Yang JC, Fogler WE, Turner EM, Alexander HR, Libutti SK.
Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.
Clin. Cancer Res. 6: 4628-34, 2000.
395)  Walther MM, Rehak NN, Venzon D, Myers CE, Linehan WM, Figg WD.
Suramin administration is associated with a decrease in serum calcium levels.
World journal of urology. 18: 388-91, 2000.
396)  Leach FS, Velasco A, Hsieh JT, Sagalowsky AI, McConnell JD.
The mismatch repair gene hMSH2 is mutated in the prostate cancer cell line LNCaP.
J. Urol. 164: 1830-3, 2000.
397)  Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B.
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
Nat. Genet. 16: 68-73, 1997.
398)  Linehan WM, Gnarra JR, Lerman MI, Latif F, Zbar B.
Genetic basis of renal cell cancer.
Important Adv. Oncol. 47-70, 1993.
399)  Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L.
Identification of the von Hippel-Lindau disease tumor suppressor gene.
Science. 260: 1317-20, 1993.
400)  Richards FM, Phipps ME, Latif F, Yao M, Crossey PA, Foster K, Linehan WM, Affara NA, Lerman MI, Zbar B.
Mapping the Von Hippel-Lindau disease tumour suppressor gene: identification of germline deletions by pulsed field gel electrophoresis.
Hum. Mol. Genet. 2: 879-82, 1993.
401)  Gnarra JR, Glenn GM, Latif F, Anglard P, Lerman MI, Zbar B, Linehan WM.
Molecular genetic studies of sporadic and familial renal cell carcinoma.
Urol. Clin. North Am. 20: 207-16, 1993.
402)  Kehlet H, Binder C, Blichert-Toft M.
Glucocorticoid maintenance therapy following adrenalectomy: assessment of dosage and preparation.
Clin. Endocrinol. (Oxf). 5: 37-41, 1976.
Click Here to View Collapsed Bibliography.

This page was last updated on 9/5/2013.